Logo image of SOPH

SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SOPH - CH1125843347 - Common Stock

5.15 USD
-0.1 (-1.9%)
Last: 1/14/2026, 8:00:03 PM
Fundamental Rating

2

Overall SOPH gets a fundamental rating of 2 out of 10. We evaluated SOPH against 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of SOPH have multiple concerns. SOPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SOPH has reported negative net income.
  • In the past year SOPH has reported a negative cash flow from operations.
  • In the past 5 years SOPH always reported negative net income.
  • In the past 5 years SOPH always reported negative operating cash flow.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With a Return On Assets value of -51.10%, SOPH is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -87.58%, SOPH is doing worse than 74.29% of the companies in the same industry.
Industry RankSector Rank
ROA -51.1%
ROE -87.58%
ROIC N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • SOPH has a better Gross Margin (67.52%) than 62.86% of its industry peers.
  • In the last couple of years the Gross Margin of SOPH has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for SOPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

  • SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SOPH has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SOPH has been increased compared to 5 years ago.
  • SOPH has a worse debt/assets ratio than last year.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -0.84, we must say that SOPH is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of SOPH (-0.84) is worse than 62.86% of its industry peers.
  • SOPH has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of SOPH (0.33) is worse than 65.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -0.84
ROIC/WACCN/A
WACC5%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • SOPH has a Current Ratio of 3.11. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
  • SOPH has a Current ratio of 3.11. This is in the better half of the industry: SOPH outperforms 65.71% of its industry peers.
  • SOPH has a Quick Ratio of 2.94. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
  • SOPH has a Quick ratio of 2.94. This is comparable to the rest of the industry: SOPH outperforms 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 2.94
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

  • The earnings per share for SOPH have decreased by -0.92% in the last year.
  • The Revenue has grown by 13.66% in the past year. This is quite good.
  • Measured over the past years, SOPH shows a very strong growth in Revenue. The Revenue has been growing by 20.78% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)13.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%22.77%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.09% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 21.47% on average over the next years. This is a very strong growth
EPS Next Y-18.82%
EPS Next 2Y31.9%
EPS Next 3Y8.09%
EPS Next 5YN/A
Revenue Next Year16.03%
Revenue Next 2Y15.82%
Revenue Next 3Y16.84%
Revenue Next 5Y21.47%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SOPH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y8.09%

More info and screens

0

5. Dividend

5.1 Amount

  • SOPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SOPHIA GENETICS SA

NASDAQ:SOPH (1/14/2026, 8:00:03 PM)

5.15

-0.1 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)12-23
Earnings (Next)05-04
Inst Owners39.28%
Inst Owner Change0.03%
Ins Owners6.43%
Ins Owner ChangeN/A
Market Cap349.43M
Revenue(TTM)73.30M
Net Income(TTM)-74.98M
Analysts86
Price Target7.48 (45.24%)
Short Float %0.05%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.93%
Min EPS beat(2)-40.66%
Max EPS beat(2)-13.2%
EPS beat(4)0
Avg EPS beat(4)-14.38%
Min EPS beat(4)-40.66%
Max EPS beat(4)-0.67%
EPS beat(8)2
Avg EPS beat(8)-8.3%
EPS beat(12)5
Avg EPS beat(12)0.72%
EPS beat(16)8
Avg EPS beat(16)4.71%
Revenue beat(2)2
Avg Revenue beat(2)4.02%
Min Revenue beat(2)2.77%
Max Revenue beat(2)5.27%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-1.89%
Max Revenue beat(4)5.27%
Revenue beat(8)3
Avg Revenue beat(8)-1.67%
Revenue beat(12)5
Avg Revenue beat(12)-1.07%
Revenue beat(16)5
Avg Revenue beat(16)-1.47%
PT rev (1m)0%
PT rev (3m)4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.77
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 6.28
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS1.08
BVpS1.26
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.1%
ROE -87.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.52%
FCFM N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.33%
Cap/Sales 11.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 2.94
Altman-Z -0.84
F-Score2
WACC5%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-18.82%
EPS Next 2Y31.9%
EPS Next 3Y8.09%
EPS Next 5YN/A
Revenue 1Y (TTM)13.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%22.77%
Revenue Next Year16.03%
Revenue Next 2Y15.82%
Revenue Next 3Y16.84%
Revenue Next 5Y21.47%
EBIT growth 1Y-1.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.31%
EBIT Next 3Y16.87%
EBIT Next 5Y18.33%
FCF growth 1Y19.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.44%
OCF growth 3YN/A
OCF growth 5YN/A

SOPHIA GENETICS SA / SOPH FAQ

What is the fundamental rating for SOPH stock?

ChartMill assigns a fundamental rating of 2 / 10 to SOPH.


Can you provide the valuation status for SOPHIA GENETICS SA?

ChartMill assigns a valuation rating of 0 / 10 to SOPHIA GENETICS SA (SOPH). This can be considered as Overvalued.


How profitable is SOPHIA GENETICS SA (SOPH) stock?

SOPHIA GENETICS SA (SOPH) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for SOPH stock?

The Earnings per Share (EPS) of SOPHIA GENETICS SA (SOPH) is expected to decline by -18.82% in the next year.